FemPulse Pioneers On Multiple Fronts
This article was originally published in Start Up
Executive Summary
Medtech start-up FemPulse is pursuing a novel neuromodulation approach to treating overactive bladder. START-UP talks to founder and president Alexandra Haessler MD, herself something of a novelty in the mostly-male world of medtech entrepreneurship.
You may also be interested in...
Neuromodulation Devices Stimulate Opportunities In Urology
Neuromodulation for urological indications, notably overactive bladder (OAB), has been dominated since the late 1990s by Medtronic’s sacral-nerve stimulation system InterStim, with the more recent addition of Cogentix Medical’s Urgent PC for tibial nerve stimulation. Yet only a fraction of OAB patients receive effective neuromodulation treatment, and several companies hope to lower barriers to this modality by developing alternative devices for urological indications.
iPLEDGE REMS: FDA Panel To Consider Changing Pregnancy Testing, Counseling Requirements
Advisory committee to discuss proposed changes to isotretinoin REMS to minimize burden and treatment delays while preventing risk of fetal exposure. Agency recommends against at-home pregnancy tests.
Pink Sheet Podcast: Moderna CEO On Capitol Hill, Xtandi March-In Rights, Tofersen Adcomm In ALS
Pink Sheet reporter and editors discuss Moderna CEO’s Stéphane Bancel’s defense of his company and COVID-19 vaccine pricing at the Senate Health, Education, Labor and Pensions Committee, the NIH denying a petition to use government march-in rights for Xtandi, and Tofersen receiving a positive US FDA advisory committee recommendation for use in ALS.